{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:50:05Z","timestamp":1782953405340,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009020","name":"University of South China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009020","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ijgc.2025.101930","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T19:28:54Z","timestamp":1746905334000},"page":"101930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival outcomes and safety of nimotuzumab combined with radiotherapy \u00b1 chemotherapy for locally advanced cervical cancer"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-6512","authenticated-orcid":false,"given":"Jiwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manbo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101930_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"10.1016\/j.ijgc.2025.101930_bib2","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10167","key":"10.1016\/j.ijgc.2025.101930_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","article-title":"Cervical cancer","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101930_bib5","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ijgc-2022-003801","article-title":"Proportions and incidence of locally advanced cervical cancer: a global systematic literature review","volume":"32","author":"Monk","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101930_bib6","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","article-title":"MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study","volume":"22","author":"P\u00f6tter","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101930_bib7","first-page":"84","article-title":"Neoadjuvant chemoimmunotherapy is effective in locally advanced cervical cancer","volume":"21","author":"Romero","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib8","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12885-017-3503-2","article-title":"Outcome and toxicity of radical radiotherapy or concurrent chemoradiotherapy for elderly cervical cancer women","volume":"17","author":"Wang","year":"2017","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101930_bib9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Mod Pathol."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-022-02287-3","article-title":"Targeted therapies for cancer","volume":"20","author":"Zhou","year":"2022","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101930_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/modpathol.2010.239","article-title":"Molecular mechanisms of epidermal growth factor receptor overexpression in patients with cervical cancer","volume":"24","author":"Schrevel","year":"2011","journal-title":"Mod Pathol."},{"issue":"10","key":"10.1016\/j.ijgc.2025.101930_bib12","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdq723","article-title":"Epidermal growth factor receptor as a biomarker for cervical cancer","volume":"22","author":"Soonthornthum","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","article-title":"Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin","volume":"1","author":"Ramakrishnan","year":"2009","journal-title":"mAbs"},{"issue":"1-2","key":"10.1016\/j.ijgc.2025.101930_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.seminoncol.2018.04.008","article-title":"Nimotuzumab: beyond the EGFR signaling cascade inhibition","volume":"45","author":"Mazorra","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijgc.2025.101930_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3389\/fphar.2017.00595","article-title":"Upregulation of HLA Class I expression on tumor cells by the anti-EGFR antibody nimotuzumab","volume":"8","author":"Garrido","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101930_bib16","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.3390\/cancers3022014","article-title":"EGFR-targeting as a biological therapy: understanding nimotuzumab\u2019s clinical effects","volume":"3","author":"Perez","year":"2011","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib17","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijgc.2025.101930_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.10.005","article-title":"A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial","volume":"88","author":"de Castro Junior","year":"2018","journal-title":"Eur J Cancer"},{"issue":"33","key":"10.1016\/j.ijgc.2025.101930_bib19","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","article-title":"Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer","volume":"41","author":"Qin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ijgc.2025.101930_bib20","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/cncr.32179","article-title":"A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer","volume":"125","author":"Patil","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ijgc.2025.101930_bib21","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.2147\/CMAR.S191134","article-title":"Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ijgc.2025.101930_bib22","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.2147\/OTT.S164071","article-title":"A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer","volume":"11","author":"Lu","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"24","key":"10.1016\/j.ijgc.2025.101930_bib23","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.21037\/atm-22-5739","article-title":"Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijgc.2025.101930_bib24","doi-asserted-by":"crossref","first-page":"12309","DOI":"10.2147\/CMAR.S282372","article-title":"Long-term results of concurrent chemoradiotherapy combined with anti-EGFR monoclonal antibody prior to surgery in locally advanced cervical cancer: a single-institute prospective study","volume":"12","author":"Qing","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"11","key":"10.1016\/j.ijgc.2025.101930_bib25","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1078-0432.CCR-14-2368","article-title":"PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy \u00b1 cetuximab in cervical cancer patients","volume":"21","author":"de la Rochefordiere","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101930_bib26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/COC.0000000000000926","article-title":"An exploratory study of neoadjuvant cetuximab followed by cetuximab and chemoradiotherapy in women with newly diagnosed locally advanced cervical cancer","volume":"45","author":"Fracasso","year":"2022","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.101930_bib27","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ijrobp.2022.09.004","article-title":"Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA","volume":"114","author":"Mayadev","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijgc.2025.101930_bib28","doi-asserted-by":"crossref","first-page":"S1279","DOI":"10.1016\/j.annonc.2023.10.032","article-title":"LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase III ENGOT-cx11\/GOG-3047\/KEYNOTE-A18 study","volume":"34","author":"Lorusso","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101930_bib29","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1200\/JCO.2024.42.16_suppl.5514","article-title":"Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: the randomized, phase 3 CC3 study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101930_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.994726","article-title":"Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: a meta-analysis of randomized controlled trials","volume":"12","author":"Yuan","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101930_bib31","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1158\/1078-0432.CCR-09-3042","article-title":"Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO foundation study","volume":"16","author":"Rojo","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00404-010-1389-1","article-title":"Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients","volume":"283","author":"Hertlein","year":"2011","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101930_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2008.12.040","article-title":"Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial","volume":"113","author":"Kurtz","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"10434","key":"10.1016\/j.ijgc.2025.101930_bib34","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijgc.2025.101930_bib35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3389\/fonc.2020.00817","article-title":"Nimotuzumab for patients with inoperable cancer of the head and neck","volume":"10","author":"Crombet Ramos","year":"2020","journal-title":"Front Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:37:04Z","timestamp":1782952624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25010503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1048891X25010503"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101930","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes and safety of nimotuzumab combined with radiotherapy \u00b1 chemotherapy for locally advanced cervical cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101930"}}